340 related articles for article (PubMed ID: 21630267)
1. Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors.
Pesonen S; Diaconu I; Cerullo V; Escutenaire S; Raki M; Kangasniemi L; Nokisalmi P; Dotti G; Guse K; Laasonen L; Partanen K; Karli E; Haavisto E; Oksanen M; Karioja-Kallio A; Hannuksela P; Holm SL; Kauppinen S; Joensuu T; Kanerva A; Hemminki A
Int J Cancer; 2012 Apr; 130(8):1937-47. PubMed ID: 21630267
[TBL] [Abstract][Full Text] [Related]
2. Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF.
Koski A; Kangasniemi L; Escutenaire S; Pesonen S; Cerullo V; Diaconu I; Nokisalmi P; Raki M; Rajecki M; Guse K; Ranki T; Oksanen M; Holm SL; Haavisto E; Karioja-Kallio A; Laasonen L; Partanen K; Ugolini M; Helminen A; Karli E; Hannuksela P; Pesonen S; Joensuu T; Kanerva A; Hemminki A
Mol Ther; 2010 Oct; 18(10):1874-84. PubMed ID: 20664527
[TBL] [Abstract][Full Text] [Related]
3. Serotype chimeric oncolytic adenovirus coding for GM-CSF for treatment of sarcoma in rodents and humans.
Bramante S; Koski A; Kipar A; Diaconu I; Liikanen I; Hemminki O; Vassilev L; Parviainen S; Cerullo V; Pesonen SK; Oksanen M; Heiskanen R; Rouvinen-Lagerström N; Merisalo-Soikkeli M; Hakonen T; Joensuu T; Kanerva A; Pesonen S; Hemminki A
Int J Cancer; 2014 Aug; 135(3):720-30. PubMed ID: 24374597
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients.
Cerullo V; Pesonen S; Diaconu I; Escutenaire S; Arstila PT; Ugolini M; Nokisalmi P; Raki M; Laasonen L; Särkioja M; Rajecki M; Kangasniemi L; Guse K; Helminen A; Ahtiainen L; Ristimäki A; Räisänen-Sokolowski A; Haavisto E; Oksanen M; Karli E; Karioja-Kallio A; Holm SL; Kouri M; Joensuu T; Kanerva A; Hemminki A
Cancer Res; 2010 Jun; 70(11):4297-309. PubMed ID: 20484030
[TBL] [Abstract][Full Text] [Related]
5. Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus.
Kanerva A; Nokisalmi P; Diaconu I; Koski A; Cerullo V; Liikanen I; Tähtinen S; Oksanen M; Heiskanen R; Pesonen S; Joensuu T; Alanko T; Partanen K; Laasonen L; Kairemo K; Pesonen S; Kangasniemi L; Hemminki A
Clin Cancer Res; 2013 May; 19(10):2734-44. PubMed ID: 23493351
[TBL] [Abstract][Full Text] [Related]
6. Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM-CSF: Results in vitro, in rodents and in humans.
Bramante S; Kaufmann JK; Veckman V; Liikanen I; Nettelbeck DM; Hemminki O; Vassilev L; Cerullo V; Oksanen M; Heiskanen R; Joensuu T; Kanerva A; Pesonen S; Matikainen S; Vähä-Koskela M; Koski A; Hemminki A
Int J Cancer; 2015 Oct; 137(7):1775-83. PubMed ID: 25821063
[TBL] [Abstract][Full Text] [Related]
7. Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumors.
Pesonen S; Nokisalmi P; Escutenaire S; Särkioja M; Raki M; Cerullo V; Kangasniemi L; Laasonen L; Ribacka C; Guse K; Haavisto E; Oksanen M; Rajecki M; Helminen A; Ristimäki A; Karioja-Kallio A; Karli E; Kantola T; Bauerschmitz G; Kanerva A; Joensuu T; Hemminki A
Gene Ther; 2010 Jul; 17(7):892-904. PubMed ID: 20237509
[TBL] [Abstract][Full Text] [Related]
8. A Multi Targeting Conditionally Replicating Adenovirus Displays Enhanced Oncolysis while Maintaining Expression of Immunotherapeutic Agents.
Dobbins GC; Ugai H; Curiel DT; Gillespie GY
PLoS One; 2015; 10(12):e0145272. PubMed ID: 26689910
[TBL] [Abstract][Full Text] [Related]
9. Tumor-specific oncolytic adenoviruses expressing granulocyte macrophage colony-stimulating factor or anti-CTLA4 antibody for the treatment of cancers.
Du T; Shi G; Li YM; Zhang JF; Tian HW; Wei YQ; Deng H; Yu DC
Cancer Gene Ther; 2014 Aug; 21(8):340-8. PubMed ID: 25034886
[TBL] [Abstract][Full Text] [Related]
10. Immunological data from cancer patients treated with Ad5/3-E2F-Δ24-GMCSF suggests utility for tumor immunotherapy.
Hemminki O; Parviainen S; Juhila J; Turkki R; Linder N; Lundin J; Kankainen M; Ristimäki A; Koski A; Liikanen I; Oksanen M; Nettelbeck DM; Kairemo K; Partanen K; Joensuu T; Kanerva A; Hemminki A
Oncotarget; 2015 Feb; 6(6):4467-81. PubMed ID: 25714011
[TBL] [Abstract][Full Text] [Related]
11. E1A, E1B double-restricted adenovirus with RGD-fiber modification exhibits enhanced oncolysis for CAR-deficient biliary cancers.
Wakayama M; Abei M; Kawashima R; Seo E; Fukuda K; Ugai H; Murata T; Tanaka N; Hyodo I; Hamada H; Yokoyama KK
Clin Cancer Res; 2007 May; 13(10):3043-50. PubMed ID: 17505007
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity.
Santos JM; Heiniö C; Cervera-Carrascon V; Quixabeira DCA; Siurala M; Havunen R; Butzow R; Zafar S; de Gruijl T; Lassus H; Kanerva A; Hemminki A
J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31940588
[TBL] [Abstract][Full Text] [Related]
13. An Oncolytic Adenovirus Encoding Decorin and Granulocyte Macrophage Colony Stimulating Factor Inhibits Tumor Growth in a Colorectal Tumor Model by Targeting Pro-Tumorigenic Signals and via Immune Activation.
Liu Z; Yang Y; Zhang X; Wang H; Xu W; Wang H; Xiao F; Bai Z; Yao H; Ma X; Jin L; Wu C; Seth P; Zhang Z; Wang L
Hum Gene Ther; 2017 Aug; 28(8):667-680. PubMed ID: 28530155
[TBL] [Abstract][Full Text] [Related]
14. Case-control estimation of the impact of oncolytic adenovirus on the survival of patients with refractory solid tumors.
Kanerva A; Koski A; Liikanen I; Oksanen M; Joensuu T; Hemminki O; Palmgren J; Hemminki K; Hemminki A
Mol Ther; 2015 Feb; 23(2):321-9. PubMed ID: 25381801
[TBL] [Abstract][Full Text] [Related]
15. Treatment of chemotherapy resistant ovarian cancer with a MDR1 targeted oncolytic adenovirus.
Rein DT; Volkmer A; Beyer IM; Curiel DT; Janni W; Dragoi A; Hess AP; Maass N; Baldus SE; Bauerschmitz G; Breidenbach M
Gynecol Oncol; 2011 Oct; 123(1):138-46. PubMed ID: 21741695
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic adenovirus ICOVIR-7 in patients with advanced and refractory solid tumors.
Nokisalmi P; Pesonen S; Escutenaire S; Särkioja M; Raki M; Cerullo V; Laasonen L; Alemany R; Rojas J; Cascallo M; Guse K; Rajecki M; Kangasniemi L; Haavisto E; Karioja-Kallio A; Hannuksela P; Oksanen M; Kanerva A; Joensuu T; Ahtiainen L; Hemminki A
Clin Cancer Res; 2010 Jun; 16(11):3035-43. PubMed ID: 20501623
[TBL] [Abstract][Full Text] [Related]
17. Conditionally replicative adenovirus with tropism expanded towards integrins inhibits osteosarcoma tumor growth in vitro and in vivo.
Witlox AM; Van Beusechem VW; Molenaar B; Bras H; Schaap GR; Alemany R; Curiel DT; Pinedo HM; Wuisman PI; Gerritsen WR
Clin Cancer Res; 2004 Jan; 10(1 Pt 1):61-7. PubMed ID: 14734452
[TBL] [Abstract][Full Text] [Related]
18. Modification of the early gene enhancer-promoter improves the oncolytic potency of adenovirus 11.
Wong HH; Jiang G; Gangeswaran R; Wang P; Wang J; Yuan M; Wang H; Bhakta V; Müller H; Lemoine NR; Wang Y
Mol Ther; 2012 Feb; 20(2):306-16. PubMed ID: 22086234
[TBL] [Abstract][Full Text] [Related]
19. Combined fiber modifications both to target α(v)β(6) and detarget the coxsackievirus-adenovirus receptor improve virus toxicity profiles in vivo but fail to improve antitumoral efficacy relative to adenovirus serotype 5.
Coughlan L; Vallath S; Gros A; Giménez-Alejandre M; Van Rooijen N; Thomas GJ; Baker AH; Cascalló M; Alemany R; Hart IR
Hum Gene Ther; 2012 Sep; 23(9):960-79. PubMed ID: 22708837
[TBL] [Abstract][Full Text] [Related]
20. Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer.
Hemminki O; Diaconu I; Cerullo V; Pesonen SK; Kanerva A; Joensuu T; Kairemo K; Laasonen L; Partanen K; Kangasniemi L; Lieber A; Pesonen S; Hemminki A
Mol Ther; 2012 Sep; 20(9):1821-30. PubMed ID: 22871667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
